Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00014
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
CGVVQQ
|
|||||
| Structure |
|
|||||
| Sequence |
CGVVQQ
|
|||||
| Peptide Type |
Linear
|
|||||
| Receptor Name |
Integrin alpha-V (ITGAV)
|
Receptor Info | ||||
| PDC Transmembrane Types | Cell targeting peptides (CTPs) | |||||
| Formula |
C25H44N8O9S
|
|||||
| Isosmiles |
[H]NC(=O)CC[C@H](NC(=O)[C@H](CCC(=O)N[H])NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CS[H])N[H])C(C)C)C(C)C)C(=O)O
|
|||||
| InChI |
InChI=1S/C25H44N8O9S/c1-11(2)19(32-18(36)9-29-21(37)13(26)10-43)24(40)33-20(12(3)4)23(39)30-14(5-7-16(27)34)22(38)31-15(25(41)42)6-8-17(28)35/h11-15,19-20,43H,5-10,26H2,1-4H3,(H2,27,34)(H2,28,35)(H,29,37)(H,30,39)(H,31,38)(H,32,36)(H,33,40)(H,41,42)/t13-,14-,15-,19-,20-/m0/s1
|
|||||
| InChIKey |
OPSDYZLPBCNMJG-QEFISFJRSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
632.741
|
Polar area
|
295
|
||
|
Complexity
|
632.295196
|
xlogp Value
|
-3.7735
|
|||
|
Heavy Count
|
43
|
Rot Bonds
|
22
|
|||
|
Hbond acc
|
10
|
Hbond Donor
|
10
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
SN38-HKD [Investigative]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Triple-negative breast cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
43% (Day 14)
|
|||
| Administration Time | 4-injection regimen (on day 0, 2, 4, and 6) | ||||
| Administration Dosage | 10 mg/kg | ||||
| Evaluation Method | Tumor volume detection assay | ||||
| MOA of PDC |
N38-HKD increases infiltration, activity, and viability of CD8+T cells, and thus inhibits the growth of primary tumors and pulmonary metastasis. This study highlights the synergistic modulation of cancerous cells and TECs with integrin-targeting PDC filaments as a promising strategy for TNBC chemoimmunotherapy.
|
||||
| Description |
SN38-HKD/RGDR slowed the 4T1 tumor growth by 74%, while irinotecan and SN38-HKD only showed 28% and 43% tumor growth inhibition, respectively, which was further confirmed by its capability in reducing tumor burden.
|
||||
| In Vivo Model | 4T1 tumor-bearing mice. | ||||
| In Vitro Model | Mammary carcinoma | 4T1 cell | CVCL_0125 | ||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Triple-negative breast cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
40% (Day 18)
|
|||
| Administration Time | 4-injection regimen (on day 0, 2, 4, and 6) | ||||
| Administration Dosage | 10 mg/kg | ||||
| Evaluation Method | Tumor volume detection assay | ||||
| MOA of PDC |
N38-HKD increases infiltration, activity, and viability of CD8+T cells, and thus inhibits the growth of primary tumors and pulmonary metastasis. This study highlights the synergistic modulation of cancerous cells and TECs with integrin-targeting PDC filaments as a promising strategy for TNBC chemoimmunotherapy.
|
||||
| Description |
SN38-HKD/RGDR slowed the 4T1 tumor growth by 74%, while irinotecan and SN38-HKD only showed 28% and 43% tumor growth inhibition, respectively, which was further confirmed by its capability in reducing tumor burden.
|
||||
| In Vivo Model | EMT6 tumor-bearing mice. | ||||
| In Vitro Model | Mammary gland malignant neoplasms | EMT6 cell | CVCL_1923 | ||
SN38-HKD/RGDR [Investigative]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Triple-negative breast cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
74% (Day 14)
|
|||
| Administration Time | 4-injection regimen (on day 0, 2, 4, and 6) | ||||
| Administration Dosage | 10 mg/kg | ||||
| Evaluation Method | Tumor volume detection assay | ||||
| MOA of PDC |
N38-HKD/RGDR increases infiltration, activity, and viability of CD8+ T cells, and thus inhibits the growth of primary tumors and pulmonary metastasis. This study highlights the synergistic modulation of cancerous cells and TECs with integrin-targeting PDC filaments as a promising strategy for TNBC chemoimmunotherapy.
|
||||
| Description |
SN38-HKD/RGDR slowed the 4T1 tumor growth by 74%, while irinotecan and SN38-HKD only showed 28% and 43% tumor growth inhibition, respectively, which was further confirmed by its capability in reducing tumor burden.
|
||||
| In Vivo Model | 4T1 tumor-bearing mice. | ||||
| In Vitro Model | Mammary carcinoma | 4T1 cell | CVCL_0125 | ||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Triple-negative breast cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
75% (Day 18)
|
|||
| Administration Time | 4-injection regimen (on day 0, 2, 4, and 6) | ||||
| Administration Dosage | 10 mg/kg | ||||
| Evaluation Method | Tumor volume detection assay | ||||
| MOA of PDC |
N38-HKD/RGDR increases infiltration, activity, and viability of CD8+T cells, and thus inhibits the growth of primary tumors and pulmonary metastasis. This study highlights the synergistic modulation of cancerous cells and TECs with integrin-targeting PDC filaments as a promising strategy for TNBC chemoimmunotherapy.
|
||||
| Description |
SN38-HKD/RGDR slowed the 4T1 tumor growth by 74%, while irinotecan and SN38-HKD only showed 28% and 43% tumor growth inhibition, respectively, which was further confirmed by its capability in reducing tumor burden.
|
||||
| In Vivo Model | EMT6 tumor-bearing mice. | ||||
| In Vitro Model | Mammary gland malignant neoplasms | EMT6 cell | CVCL_1923 | ||
References